BAY 94-9027 (Bayer) is a long-acting recombinant factor VIII (rfVIII) product under development for the treatment of hemophilia A. To extend its half-life, BAY 94-9027 is produced via the conjugation of a 60kDa polyethylene glycol molecule to a cysteine residue on the light chain of B-domain deleted rfVIII.
Bayer is developing BAY 94-9027 as the successor to its Kogenate/Kovaltry franchise as the treatment landscape shifts towards longer-acting injections that are more amendable to long-term prophylactic therapy. Bayer filed global regulatory applications for BAY 94-9027 in 2017, with first commercial availability expected from H2 2018.
TABLE OF CONTENTS
4 Drug Overview
5 Product Profiles
5 BAY 94-9027 : Hemophilia
LIST OF FIGURES
8 Figure 46: NovoEight for hemophilia – SWOT analysis
9 Figure 63: Rebinyn sales for hemophilia across the US, Japan, and five major EU markets, by country, 2016–25
12 Figure 47: NovoEight sales for hemophilia across the US, Japan, and five major EU markets, by country, 2016–25
14 Figure 46: Datamonitor Healthcare’s drug assessment summary of NovoSeven for hemophilia
LIST OF TABLES 6 Table 1: BAY 94-9027 drug profile
7 Table 2: BAY 94-9027 Phase III data in hemophilia
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.